diabetes - Nursing Case Study

Pathophysiology

• Insulin resistance: In type 2 diabetes, cells in muscles, fat, and the liver become resistant to insulin's effects, necessitating higher insulin production, which the pancreas cannot sustain, leading to hyperglycemia.

• Beta-cell dysfunction: Chronic hyperglycemia and increased metabolic demand lead to the progressive dysfunction and apoptosis of pancreatic beta-cells, reducing insulin secretion and exacerbating hyperglycemia.

• Key complication: Persistent hyperglycemia causes microvascular damage, resulting in retinopathy, nephropathy, and neuropathy, which can progress to blindness, kidney failure, and limb amputations, respectively.

Patient Profile

Demographics:

57-year-old male, truck driver

History:

• Key past medical history: Type 2 diabetes for 15 years, hypertension, hyperlipidemia, chronic kidney disease stage 3, diabetic retinopathy

• Current medications: Metformin, insulin glargine, lisinopril, atorvastatin, aspirin, furosemide

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Severe fatigue and shortness of breath

• Key symptoms: Blurred vision, frequent urination, increased thirst, leg swelling, numbness in feet

• Vital signs: Blood pressure 180/110 mmHg, heart rate 110 bpm, respiratory rate 24 breaths per minute, temperature 97.8°F, oxygen saturation 88% on room air, blood glucose 450 mg/dL

Section 1

Initial assessment findings reveal that the patient exhibits signs of severe decompensated heart failure and potential diabetic ketoacidosis (DKA). The patient's oxygen saturation of 88% on room air, coupled with a high respiratory rate of 24 breaths per minute, suggests inadequate oxygenation and possible pulmonary congestion. Upon auscultation, crackles are present bilaterally in the lower lung fields, and jugular venous distention is noted, supporting the suspicion of heart failure exacerbation. The patient also demonstrates significant pitting edema in both lower extremities, consistent with fluid overload. The elevated blood pressure of 180/110 mmHg indicates poorly controlled hypertension, which may further strain cardiac function.

Laboratory results return alarming findings: arterial blood gas analysis shows metabolic acidosis with a pH of 7.25, bicarbonate level of 15 mEq/L, and an elevated anion gap, aligning with a diagnosis of DKA. Additionally, serum potassium is critically low at 2.8 mEq/L, necessitating immediate intervention. Further labs reveal a worsening renal function with a serum creatinine of 2.5 mg/dL, indicating progression of chronic kidney disease. The patient's hemoglobin A1c is markedly elevated at 11.5%, underscoring chronic poor glycemic control. These findings necessitate urgent adjustments in management, including aggressive insulin therapy, fluid resuscitation, potassium replacement, and diuretics to address heart failure symptoms while carefully monitoring renal function.

The critical nature of the patient's condition requires swift clinical judgment and prioritization of interventions. Initiating an insulin infusion while managing electrolyte imbalances poses a significant challenge due to the risk of hypokalemia-induced cardiac arrhythmias. Coordination with the nephrology and cardiology teams is essential to optimize fluid management, especially in the context of impaired renal function and potential fluid shifts. As the patient's status evolves, careful monitoring of vital signs, blood glucose levels, and electrolyte panels will be crucial in guiding treatment adjustments and preventing further complications such as arrhythmias, worsening heart failure, or acute kidney injury.

Section 2

As the medical team initiates treatment, the patient's condition takes a concerning turn. Despite aggressive insulin therapy and initial fluid resuscitation, the patient exhibits signs of deteriorating respiratory status. Oxygen saturation drops further to 84% on room air, prompting the need for supplemental oxygen via a non-rebreather mask. Repeat auscultation reveals worsening crackles that have ascended to the mid-lung fields, suggesting increased pulmonary congestion. The patient's respiratory rate escalates to 28 breaths per minute, indicating increased respiratory distress and possible impending respiratory failure.

Concurrent with these respiratory changes, the patient's neurological status begins to decline. Previously alert and oriented, the patient now appears lethargic and disoriented, raising concerns about cerebral hypoxia or potential cerebral edema secondary to severe metabolic derangements. A repeat arterial blood gas analysis reveals persistent metabolic acidosis with a pH of 7.20, alongside a further drop in serum bicarbonate to 12 mEq/L. Potassium replacement has only marginally improved serum potassium to 3.0 mEq/L, still leaving the patient at risk for cardiac complications.

Given the complexity of these developments, the healthcare team must exercise advanced clinical reasoning to reassess and adjust the treatment plan. Prioritizing stabilization of respiratory function, intubation may become necessary to maintain adequate oxygenation and prevent further neurological compromise. Coordination with cardiology remains crucial to balance the diuretic therapy required for heart failure management without exacerbating renal impairment or electrolyte imbalances. The unfolding situation demands meticulous monitoring and collaboration across specialties to navigate the intersecting challenges of heart failure, DKA, and impaired renal function, ensuring comprehensive and responsive care to avert further complications.

Section 3

As the medical team intensifies their efforts to stabilize the patient, a new set of diagnostic results arrives, shedding light on the multifaceted complications at play. A chest X-ray confirms significant bilateral pulmonary edema, consistent with acute decompensated heart failure, likely exacerbated by the fluid shifts and metabolic stress of diabetic ketoacidosis (DKA). Meanwhile, an echocardiogram reveals a severely reduced ejection fraction of 30%, underscoring the urgent need for effective cardiac management and adjustment of current treatment protocols.

Further laboratory investigations unveil a concerning renal panel: serum creatinine has risen to 3.2 mg/dL, and blood urea nitrogen (BUN) is elevated at 52 mg/dL, suggesting acute kidney injury (AKI) possibly secondary to hypoperfusion and volume overload. This renal impairment complicates the administration of diuretics, as aggressive fluid removal could further compromise renal function. Meanwhile, the patient's serum sodium is critically low at 128 mEq/L, increasing the risk of neurological sequelae such as seizures or worsening cerebral edema.

These diagnostic revelations prompt the healthcare team to reconsider the current management strategy. The focus shifts to a delicate balance of optimizing cardiac output while supporting renal function. A nephrology consult is obtained to weigh the risks and benefits of renal replacement therapy, while cardiology advises cautious titration of inotropes and vasodilators. The team also explores the possibility of initiating continuous renal replacement therapy (CRRT) to manage fluid overload without exacerbating the metabolic derangements. With these new insights, the multidisciplinary team adjusts the therapeutic approach, emphasizing the need for continuous reassessment and adaptation to the rapidly evolving clinical picture.

Section 4

As the healthcare team implements the revised treatment plan, the patient's status begins to show subtle yet critical changes. Over the next 12 hours, continuous monitoring reveals fluctuating hemodynamics; the patient's blood pressure stabilizes at 105/68 mmHg with a heart rate of 110 beats per minute, yet the respiratory rate remains elevated at 28 breaths per minute with persistent use of accessory muscles, indicating ongoing respiratory distress. Arterial blood gases show a pH of 7.29, PaCO2 of 30 mmHg, and HCO3- of 14 mEq/L, suggesting the patient is still in a state of metabolic acidosis with partial respiratory compensation.

Despite cautious titration of inotropes, there is minimal improvement in cardiac output, and the patient's urine output declines to less than 0.3 mL/kg/hr, raising alarms about worsening renal function. A repeat serum electrolyte panel reveals further hyponatremia with sodium dropping to 125 mEq/L, and hyperkalemia with potassium levels rising to 5.8 mEq/L, which complicates the cardiac management strategy due to the risk of arrhythmias.

Meanwhile, the implementation of continuous renal replacement therapy (CRRT) begins to show promise in managing the fluid overload, with a gradual reduction in pulmonary edema observed on subsequent chest X-rays. However, the patient develops new-onset confusion and restlessness, warranting a neurological assessment to rule out cerebral edema or an osmotic demyelination syndrome as potential complications of the rapid electrolyte shifts. These developments necessitate a multidisciplinary discussion to re-evaluate the therapeutic priorities and consider the potential need for more aggressive interventions to stabilize the patient's precarious condition.

Section 5

As the healthcare team shifts focus to the patient's neurologic status, a comprehensive assessment is conducted. The patient's confusion and restlessness have progressed to periods of agitation interspersed with lethargy. Neurological examination reveals an altered level of consciousness, with a Glasgow Coma Scale score dropping to 10, characterized by a decline in verbal and motor responses. Pupillary reactions are sluggish, and there is a significant delay in response to light. These changes coincide with the initiation of CRRT, raising concerns about rapid shifts in serum osmolality.

A stat brain MRI is ordered to assess for cerebral edema or other intracranial pathology. The imaging results reveal diffuse cerebral edema without evidence of focal lesions or hemorrhage, pointing toward osmotic demyelination syndrome as a potential consequence of the electrolyte imbalances. Concurrently, laboratory results indicate an improvement in metabolic parameters: the serum sodium has corrected to 132 mEq/L, and potassium levels have normalized to 4.5 mEq/L. Despite these improvements, the patient's neurological status remains compromised, necessitating an urgent reassessment of the current treatment strategy.

In response to these findings, the multidisciplinary team convenes to discuss the immediate need to balance the correction of metabolic derangements with careful monitoring of neurological function. The decision is made to slow the rate of CRRT to mitigate further cerebral insult while maintaining vigilant monitoring of neurologic status. Additionally, the team considers the introduction of neuroprotective measures and consults neurology for potential interventions to address the cerebral edema. The patient's journey continues to present challenges, necessitating a dynamic approach to management, where each intervention is carefully evaluated for its impact on the complex interplay of systemic and neurologic stability.